Back to Search
Start Over
Effectiveness of drugs acting on adrenergic receptors in the treatment for tobacco or alcohol use disorders: systematic review and meta‐analysis
- Source :
- Addiction, Addiction, Wiley, 2021, 116 (5), pp.1011-1020. ⟨10.1111/add.15265⟩, Addiction, Wiley, 2020, 116 (5), ⟨10.1111/add.15265⟩, Addiction, 2021, 116 (5), pp.1011-1020. ⟨10.1111/add.15265⟩
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- International audience; Aim : To assess the efficacy of drugs directly acting on alpha- and beta-adrenergic receptors in the treatment of patients suffering from tobacco or alcohol use disorder.Methods : Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, studies were identified through PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials and clinicaltrial.gov. We selected only randomized controlled trials with adult patients with tobacco or alcohol use disorders according to DSM-5 criteria. Interventions included any molecule having a direct pharmacological action on alpha- or beta-adrenergic receptors (agonist or antagonist). Comparators were placebo or other validated pharmacotherapies. The duration of the intervention was a minimum of 1 month, with 3 months of follow-up. Measurements included smoking cessation for tobacco; for alcohol, we selected abstinence, alcohol consumption (drinks per day or week) and heavy drinking days (HDD). Ten studies with tobacco and six with alcohol use disorder were included in the qualitative synthesis and fifteen studies in the quantitative analysis.Results: We found that clonidine, an alpha-2 agonist, significantly increased smoking abstinence [relative risk = 1.39 with a 95% confidence interval (CI) = 1.04, 1.84]. Beta-blockers had no significant effect on smoking abstinence. The alpha-1 antagonists prazosin and doxazosin decreased alcohol consumption [SMD = −0.32 (−0.56, −0.07)] but had no effect on abstinence or HDD.Conclusions : The noradrenaline system may represent a promising mechanism to target in tobacco and alcohol use disorders.
- Subjects :
- Adult
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
media_common.quotation_subject
adrenergic blockers
030508 substance abuse
Medicine (miscellaneous)
Alcohol use disorder
alcohol use disorder
Placebo
beta-adrenergic receptors
alpha-adrenergic receptors
law.invention
tobacco use disorder
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Tobacco
Humans
Medicine
030212 general & internal medicine
media_common
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
Adrenergic agonists
business.industry
[SCCO.NEUR]Cognitive science/Neuroscience
[SCCO.NEUR] Cognitive science/Neuroscience
Abstinence
medicine.disease
Receptors, Adrenergic
3. Good health
Clonidine
Alcoholism
Psychiatry and Mental health
Systematic review
Pharmaceutical Preparations
Meta-analysis
Smoking cessation
Smoking Cessation
0305 other medical science
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
medicine.drug
Subjects
Details
- ISSN :
- 13600443 and 09652140
- Volume :
- 116
- Database :
- OpenAIRE
- Journal :
- Addiction
- Accession number :
- edsair.doi.dedup.....07cee21c34c9cc12c86f325516b4dbc2